Saccharide-modified nucleic acid molecules
US10751425B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Jan 15, 2015 |
| Grant date | Aug 25, 2020 |
| Priority date | — |
| Expiry date | Jun 5, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2320/32
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention refers to the transfection of cells using a conjugate comprising at least one saccharide residue at least one nucleosidic component selected from nucleic acids, nucleosides and nucleotides. This conjugate is suitable for the transfection of prokaryotic and eukaryotic cells such as plant cells or mammalian cells including human cells with high efficacy. Thus, a new delivery vehicle for therapeutic molecules including antisense molecules, sRNA molecules, miRNA molecules, antagomirs or precursors of such molecules, as well as the therapeutic nucleosides or nucleotides, is provided. Further, a convenient strategy for developing new lines of plants that exhibit particular traits is provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.